Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
NeuroImage: Clinical
These medications are used primarily by those with diabetes or obesity, with weight loss being one of the benefits that attracts users
It is supplied in multiple-dose vials and is indicated only for diluting or dissolving drugs for intravenous, intramuscular, or subcutaneous injection, following the instructions of the manufacturer of the drug being given
The SURMOUNT-5 trial (Rosenstock et al., Lancet 2025) showed 24.2% mean weight loss at 48 weeks, compared to 15.7% for semaglutide 2.4 mg
Ulodesine displays no interactions with CYP450 isoforms and undergoes no hepatic metabolism, thereby minimizing anticipated drug interactions
US$ 22.36
US$ 25.12
US$ 22.35
